Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

the 31 patients with stable disease or better, one

patient had a complete response and four patients had partial

responses (two unconfirmed).

-- SNS-595 has been generally well tolerated in this trial, with a low

rate of febrile neutropenia or other Grade 3/4 adverse events and

manageable Grade 1/2 nausea or vomiting. Based on the drug's

observed safety profile and indications of clinical activity,

Sunesis amended the protocol to explore a higher dose of SNS-595 in

this trial. Enrollment has begun at a dose of 60 mg/m2 over twenty-

eight days, and Sunesis anticipates enrolling approximately 30

patients at this dose in the third quarter of this year.

-- Data from this trial has been accepted for presentation at the 44th

ASCO Annual Meeting.

-- Sunesis updated the results from the company's Phase 1 clinical trial

of single-agent SNS-595 in patients with relapsed or refractory acute

leukemias, which had previously been reported at the 49th Annual

Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia

in December 2007. Since the ASH presentation, an additional patient in

this trial has achieved a complete remission.

-- Twelve of 30 patients (43 percent) who received doses of SNS-595 of

50 mg/m2 or greater on a weekly dose schedule have now achieved bone

marrow blast reductions to less than five percent, and five of these

12 patients achieved either complete remission, complete remission

without platelet recovery or complete remission with incomplete

recovery of normal hematopoietic blood elements.

-- SNS-595 was generally well tolerated in this trial, with a

dose-limiting toxicity of reversible Grade 3/4 oral mucositis.

-- Based on these promising results, Sunesis
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... over 60 are not donor candidates for bone marrow ... making the elderly prone to life-threatening infection and other ... has discovered a reason why. , "We have found ... cells to maintain blood production over time in an ... be restored for rejuvenation therapies," said Emmanuelle Passegu, PhD, ...
(Date:7/31/2014)... SPRINGS, Colo. , July 31, 2014 /PRNewswire-USNewswire/ ... Grant awardee today with $25,000 to fund a ... Foundation,s inception in 2011, the gift was presented ... th Annual Meeting in Colorado ... who specialize in neurointerventional approaches to neurovascular conditions, ...
(Date:7/31/2014)... York , July 31, 2014 ... Transparency Market Research "Electrodes for Medical Devices Market (Diagnostic ... Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and ... Trends and Forecast, 2013 - 2019," the global electrodes ... million in 2012 and is estimated to reach a ...
(Date:7/31/2014)... and SHENZHEN, China , July ... today the purchase of an Irys™System by ... selected BioNano,s platform to enable comprehensive exploration of human ... for various organisms of interest, including those where no ... together to develop new methods for multiplexing on the ...
Breaking Biology Technology:Key to aging immune system is discovered 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4
... KENILWORTH, N.J., Sept. 18 The Board of Directors of ... dividend of 6.5 cents per common share. Payment will be ... close of business on Oct. 26, 2009. As of June ... , The Board of Directors today also declared a ...
... LONDON, September 18 London Genetics ... London-based centres of excellence in genetics research, announces ... team. The new,appointments, which include Dr Barrie Ward ... company,s growth as the importance of pharmacogenetics in ...
... , SAN FRANCISCO, Sept. 18 Jennerex, Inc. (San ... a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today ... with aggregate gross proceeds of US $5,611,475, exceeding the target of ... reported, the net proceeds of the private placement will be used ...
Cached Biology Technology:New Appointments at London Genetics to Drive Strategy Forward 2New Appointments at London Genetics to Drive Strategy Forward 3New Appointments at London Genetics to Drive Strategy Forward 4Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million 2Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million 3
(Date:7/31/2014)... Orleans, LA Dr. Oren Tessler, Assistant Professor of ... School of Medicine, is part of a team of ... rate using a method to screen and select patients ... 90% of the patients who underwent this surgery to ... also got a bonus cosmetic eyelid surgery. The study, ...
(Date:7/31/2014)... TALLAHASSEE, Fla. A Florida State University researcher found ... of the toxic components of the oil released during ... spill, but not the most toxic contaminants. , In ... Assistant Professor Olivia Mason found a species of bacteria ... perhaps benzene, toluene, ethylbenzene and xylene compounds that were ...
(Date:7/31/2014)... Biometrics industry sees growth as ... companies turn towards digital currency: NXT-ID, Inc. (OTCBB: NXTD), ... (NASDAQ: AMZN ), Facebook Inc. (NASDAQ: ... ) and Microsoft Corporation (NASDAQ: MSFT) NXT-ID, Inc., ... m-commerce market, announces a video featuring its next generation ...
Breaking Biology News(10 mins):Surgeons report significant migraine relief from cosmetic eyelid surgery technique 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 3Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 4Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 6
... University of Exeter biologist has discovered a ,lost, species of bat ... long-eared bat is the first of its species to be found ... by Dr Fiona Mathews, Senior Lecturer at the University of Exeter, ... The Scilly Isles Bat Group called in Dr Mathews and ...
... University of Adelaide computer scientists are developing image-based ... of improved cereal varieties for the harsher environmental conditions ... van den Hengel, Director of the Australian Centre for ... plant physiologists and an industry partner to develop technology ...
... bacteria that cause Lyme disease, one of the most ... hide out in the lymph nodes, triggering a significant ... to rout the infection, report researchers at the University ... involving mice may explain why some people experience repeated ...
Cached Biology News:'Lost' bats found breeding on Scilly 2Imaging cereals for increased crop yields 2Lyme disease bacteria take cover in lymph nodes 2
... aa 16-25 of human GSK3 alpha. ... Store vial at -20 C prior to opening. Dilute ... and freeze at -20 C or below. Avoid cycles ... Sub-Family: not assigned-Other ...
... ligase (AMP forming), Acetate thiokinase ... Physical form: Lyophilized powder containing ... glutathione Preparation Unit Definition: One ... coenzyme A from acetate, ATP and coenzyme ...
...
... PGF2α is a metabolically stable ... a potent uterine stimulant and ... intramuscularly to induce labor. It ... progesterone concentrations when given as ...
Biology Products: